{"id":"W3031942086","doi":"10.1200/jco.2020.38.15_suppl.5001","title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Interim analysis; Renal cell carcinoma; Axitinib; Clinical endpoint; Internal medicine; Discontinuation; Temsirolimus; Pazopanib; Oncology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006748543,0.0009119796,0.002304837,0.0007036338,0.0001833267,0.0009967781,0.001255452,0.0007170266,0.003968157],"category_scores_gemma":[0.004341916,0.0004705092,0.004145494,0.000935832,0.0002163488,0.0008370796,0.000554496,0.001794494,0.0005164234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115223,"about_ca_system_score_gemma":0.0009494016,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001358089,"about_ca_topic_score_gemma":0.004535204,"domain_scores_codex":[0.997918,0.001157045,0.0001529371,0.0002331336,0.0003967095,0.0001421194],"domain_scores_gemma":[0.9976605,0.0009680912,0.0008087529,0.0001895071,0.0001447887,0.0002283863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7086736,0.003170744,0.02435169,0.004504931,0.03243637,0.0001815573,0.0001649416,0.005467623,0.007043122,0.0003159134,0.00629483,0.2073947],"study_design_scores_gemma":[0.4261715,0.1876019,0.2545424,0.0006567017,0.09436292,0.001033561,0.0001222808,0.007543468,0.00439864,0.0008635775,0.02255032,0.0001527157],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9123289,0.05124718,0.004386304,0.001391426,0.0003399275,0.003846269,0.01870705,0.0003256898,0.007427172],"genre_scores_gemma":[0.9724559,0.009792332,0.002612389,0.001067762,0.0003295861,0.0008777286,0.01036786,0.00005822935,0.002438214],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006748543,"threshold_uncertainty_score":0.03569013,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1829514474236072,"score_gpt":0.445034088241107,"score_spread":0.2620826408174998,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}